Endpoints in respiratory diseases
Authors:
- On Behalf Of The Teddy European Network Of ExcellenceOEOn Behalf Of The Teddy European Network Of Excellence
- Eugenio BaraldiEBEugenio Baraldi
- 23 November 2010
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 67 (S1) , 49-59
Abstract
A wide range of outcome measures or endpoints has been used in clinical trials to assess the effects of treatments in paediatric respiratory diseases. This can make it difficult to compare treatment outcomes from different trials and also to understand whether new treatments offer a real clinical benefit for patients. Clinical trials in respiratory diseases evaluate three types of endpoints: subjective, objective and health-related outcomes. The ideal endpoint in a clinical trial needs to be accurate, precise and reliable. Ideally, the endpoint would also be measured with minimal risk and across all ages, easy to perform, and be inexpensive. As for any other disease, endpoints for respiratory diseases must be viewed in the context of the important distinction between clinical endpoints and surrogate endpoints. The association between surrogate endpoints and clinical endpoints must be clearly defined for any disease in order for them to be meaningful as outcome measures. The most common endpoints which are used in paediatric trials in respiratory diseases are discussed. For practical purposes, diseases have been separated into acute (bronchiolitis, acute viral-wheeze, acute asthma and croup) and chronic (asthma and cystic fibrosis). Further development of endpoints will enable clinical trials in children with respiratory diseases with the main objective of improving prognosis and safety.Keywords
This publication has 42 references indexed in Scilit:
- Inter‐observer agreement between physicians, nurses, and respiratory therapists for respiratory clinical evaluation in bronchiolitisPediatric Pulmonology, 2009
- Cystic fibrosisThe Lancet, 2009
- Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezingJournal of Allergy and Clinical Immunology, 2008
- Endpoints for Clinical Trials in Young Children with Cystic FibrosisProceedings of the American Thoracic Society, 2007
- An Overview of Endpoints for Cystic Fibrosis Clinical Trials: One Size Does Not Fit AllProceedings of the American Thoracic Society, 2007
- Delivery of bronchodilators in acute asthma in childrenEmergency Medicine Journal, 2006
- Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezingPediatric Pulmonology, 2005
- Monitoring response to treatment in asthma management: food for thoughtClinical & Experimental Allergy, 2004
- β-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: A systematic review with meta-analysisThe Journal of Pediatrics, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001